Evaluation of the Eiken latex agglutination test for anti-Toxoplasma antibodies and seroprevalence of Toxoplasma infection among factory workers in Addis Ababa, Ethiopia

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 92, Issue 4, 1998, Pages 401-403

  Woldemichael, Tilahun ^a,b   Fontanet, Arnaud L ^b   Sahlu, Tefera ^b   Gilis, Henk ^c   Messele, Tsehaynesh ^b   De Rinke Wit, Tobias F ^b   Yeneneh, Hailu ^b   Coutinho, Roel A ^d   Van Gool, Tom ^c  

^a Department of Infectious and NonInfectious Diseases ^*  (Netherlands)

^b ETHIOPIAN PUBLIC HEALTH INSTITUTE   (Ethiopia)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d MUNICIPAL HEALTH SERVICE   (Netherlands)

Author keywords

Chemoprophylaxis; Ethiopia; Human immunodeficiency virus 1; Seroprevalence; Toxoplasma gondii; Toxoplasmosis

Indexed keywords

CD4 ANTIGEN; COTRIMOXAZOLE; IMMUNOGLOBULIN G ANTIBODY; PARASITE ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENCEPHALITIS; ETHIOPIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATEX AGGLUTINATION TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; SCREENING; SEROPREVALENCE; T LYMPHOCYTE; TOXOPLASMOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PROTOZOA; TOXOPLASMA; TOXOPLASMA GONDII;

EID: 0031706076     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(98)91065-3     Document Type: Article

References (27)

1. Antinori, A., Murri, R., Ammassari, A., De Luca, A., Linzanole, A., Cingaloni, A., Damiano, F., Maiuro, G., Vecchiet, J., Scoppettuolo, G., Tamburrini, E. & Otona, L. (1995). Aerosolized pentamidine, co-trimoxazole and dapsone-pyrimethamine for primary prophylaxis of pneumonia and toxoplasmic encephalitis. AIDS, 9, 1343-1350.
2. Balfour, A. H., Fleck, D. G., Hughes, H. P. A. & Sharp, D. (1982). Comparative study of three tests (dye test, indirect haemagglutination test, latex agglutination test) for the detection of antibodies to Toxoplasma gondii in human sera. Journal of Clinical Pathology, 35, 228-232.
3. Candolfi, E., Partisani, M. L., De Mautort, E., Bethencourt, S., Frantz, M., Kien, T. & Lang, J. M. (1992). Séroprevalence de la toxoplasmose chez 346 sujets infectés par le VIH dans l'est de la France: suivi sérologique des sujets non contaminés par Toxoplasma gondii. Presse Médicale, 21, 394-395.
4. Dehovitz, J. A., Pape, J. W., Boney, M. & Johnson, W. D. (1986). Clinical manifestations and therapy of Isospora belli in patients with AIDS. New England Journal of Medicine, 315, 87-90.
5. Derouin, F., Thulliez, P. & Garin,Y. J. F. (1991). Intérêt et limites de la sérologie de la toxoplasmose chez les sujets VIH+. Pathologie et Biologie, 39, 255-259.
6. Derouin, F., Leport, C., Pueyo, S., Morlat, P., Letrillat, B., Chene, G., Ecobichon, J. L., Salamon, R. & ANRS 005/ ACTG 154 Trial Group (1996). Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. AIDS, 10, 1521-1527.
7. Doehring, E., Reiter Owona, I., Bauer, O., Kaisi, M., Hlobil, H., Quade, G., Hamudu, N. A. & Seitz, H. M. (1995). Toxoplasma gondii antibodies in pregnant women and their new-borns in Dar es Salaam, Tanzania. American Journal of Tropical Medicine and Hygiene, 52, 546-548.
8. Eshete, H., Tessema S., Abebe, A. & Abebe, S. (1994). Some notes on toxoplasmosis in pregnant women in Ethiopia. Ethiopian Medical Journal, 32, 135-136.
9. Guebre-Xabier, M., Nurilign, A., Gebre-Hiwot, A., Hailu, A., Sissay,Y., Getachew, E. & Frommel, D. (1993). Sero-epidemiological survey of Toxoplasma gondii infection in Ethiopia. Ethiopian Medical Journal, 31, 201-208.
10. Grant, I. H., Gold, J. W. M., Rosenblum, M., Niedzwiecki, D. & Armstrong, D. (1990). Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS, 4, 519-521.
11. Hardy, W. D., Feinberg, J., Finklestein, D. M., Power, M. E., He, W., Kaczka, C., Frame, P. T., Holmes, M., Waskin, H., Fass, R. J., Powderly, W. G., Steibigel, P. T., Zuger, A. & Holzman, R. S. (1992). A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine, 327, 1842-1848.
12. Hirschtick, R. E., Glassroth, J., Jordan, M. C., Wilcosky, T. C., Wallace, J. M., Kvale, P. A., Markowitz, N., Rosen, M. J., Mangura, B. T., Hopewell, P. C. & The Pulmonary Complications of HIV Infection Study Group (1995). Bacterial pneumonia in persons infected with the human immunodeficiency virus. New England Journal of Medicine, 333, 845-851.
13. Israelski, D. M., Chmiel, J. S., Poggensee, L., Phair, J. P. & Remington, J. S. (1993). Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. Journal of the Acquired Immune Deficiency Syndrome, 64, 414-418.
14. Jones, J. L., Hanson, D. L., Chu, S. Y., Ciesielski, C. A., Kaplan, J. E., Ward, J. W, Navin, T. R. & the Adult/Adolescent Spectrum of Disease Group (1996).Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends. AIDS, 10, 1393-1399.
15. Kaplan, J. E., Hu, D. J., Holmes, K. K., Jaffe, H. W, Masur, H. & De Cock, K. M. (1996). Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. American Journal of Tropical Medicine and Hygiene, 55, 1-11.
16. Kobayashi, A., Hirai, N., Suzuki, Y., Nishikawa, H. & Watanabe, N. (1977). Evaluation of a commercial toxoplasma latex agglutination test. Japanese Journal of Parasitology, 26, 175-180.
17. Lester, J. (1983). Detection of antibodies to Toxoplasma gondii: a comparison of three test kits. Medical Laboratory Sciences, 40, 387-389.
18. Mengesha, B., Theodros, T. & Mohammed, M. (1984). Seroepidemiological survey of Toxoplasma gondii infection in Addis Ababa, Ethiopia. Ethiopian Medical Journal, 22, 214 [abstract].
19. Oksenhendler, E., Charreau, I., Tournerie, C., Azihary, M., Carbon, C. & Aboulker, J. P. (1994). Toxoplasma gondii infection in advanced HIV infection. AIDS, 8, 483-487.
20. Roever-Bonnet, H. de (1972). Toxoplasmosis in tropical Africa. Tropical and Geographical Medicine, 24, 7-13.
21. Sabin, A. & Feldman, H. A. (1948). Dyes as microbial indicators of a new immunity phenomenon affecting a protozoan parasite (Toxoplasma). Science, 108, 660-663.
22. Schneider, M. M., Hoepelman, A. I., Eeftinck Schattenkerk, J. K., Nielsen, T. L., van der Graaf, Y., Frissen, J. P., Van der Ende, I. M., Kolsters, A. F. & Borlefs, J. C. (1992). A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. New England Journal of Medicine, 327, 1836-1841.
23. Schneider, M. M. E., Nielsen, T. L., Nelsing, S., Hoepelman, A. I. M., Schattenkerk, J. K. M. E., van der Graaf, Y., Kolsters, A. F. P., Borleffs, J. C. C. & The Dutch AIDS Treatment Group (1995). Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Journal of Infectious Diseases, 171, 1632-1636.
24. Tsega, E. & Belihu, A. (1980). Toxoplasmosis in hospitalized Ethiopians with lymphadenopathy. East African Medical Journal, 57, 35-38.
25. USPHS/IDSA [Prevention of Opportunistic Infections Working Group] (1995). USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clinical Infectious Diseases, 21, supplement, 532-543.
26. Walker, J., Nokes, D. J. & Jennings, R. (1992). Longitudinal study of Toxoplasma seroprevalence in South Yorkshire. Epidemiology and Infection, 108, 99-106.
27. Walls, K. W. & Rimington, J. S. (1983). Evaluation of a commercial latex agglutination method for toxoplasmosis. Diagnostic Microbiology and Infectious Disease, 1, 265-271.